Proof of Concept Studies
With individualized programs in the offering, we offer a fast-track early-stage development service for your ADC and bioconjugate program to meet your needs.
Tailored to meet your needs
Cost-effective proof-of-concept conjugation service to demonstrate the viability of cytotoxic drugs or monoclonal antibodies for use as therapeutic ADCs.
Customer antibodies for conjugation suitability
- Comparison of different chemistries (cysteine and lysine)
- Range of different linkers available (cleavable, non-cleavable, and PEGylated)
- Variety of payloads available (microtubule disrupting drugs, DNA damaging compounds, protein ribosome-inactivating toxins, and chelators for radioimmunotherapy)
- Preparation of different drug loadings
- Analytical characterization and screening of conjugates
Customer cytotoxic or linker technologies
- Ability to make various conjugates with model antibodies using linker or drug platforms
- Experienced with a range of novel linker technologies
ADC Standards to Benchmark Client Materials
- A model antibody with DAR 2 and DAR 4 with different ADC toxins